MTSR: Metsera Inc Company Buyout Price

Market price action on GURU.Markets shows that Metsera Inc (MTSR) has an Enterprise Value of 6983.88. Metsera Inc (MTSR) management aims to create the most user-friendly obesity treatments. The business relies on a sophisticated component delivery system that eliminates supply chain disruptions. Simultaneously, the company is accelerating the development of innovative oral and injectable forms to rapidly capture the premium market segment.

MTSR (metsera.com) Total Company Value history from 11/23/2025 to 11/29/2025

Metsera Inc (MTSR) - metric breakdowns and financial figures

- price and consensus price forecast:

Price Metsera, Inc.|MTSR - Price Target Chart

- market capitalization data:

Market Capitalization Metsera|MTSR - Total Company Value

- book capitalization data:

Accounting Value of a Share Metsera|MTSR - Company Book Value|Market Capitalization to Net Assets metsera.com|MTSR - Company Total Assets

- debt and liquidity data:

All Debt to Shareholders' Equity Ratio Metsera Inc|MTSR - Long-Term Debt to Capital|Short-Term Debt to Capital metsera.com|MTSR - Company Debts|Debt to Net Assets Ratio Metsera

Comprehensive company analysis:Metsera, Inc. (MTSR)

Enterprise value combines market capitalization and net debt, reflecting the actual cost of a full business buyout accounting for all liabilities and liquidity. The enterprise value trend allows for an assessment of whether the diversified anti-obesity drug portfolio of Metsera Inc (MTSR) justifies the asset's current valuation scale in the eyes of professional investors.

Competitor analysis for Metsera Inc

Ascendis Pharma AS - Aggregate Business Value|Total Company Value MDGL (Madrigal Pharma)|CORT: Company Buyout Price|Total Company Value Rhythm Pharmaceuticals RYTM|AKRO (akerotx.com) - Value Adjusted for Debt and Cash|Total Company Value MoonLake MLTX|Full Business Value Crinetics Pharmaceuticals, Inc.|NewAmsterdam Pharma N.V. (NAMS) - Enterprise Value|Value Adjusted for Debt and Cash Soleno Therapeutics Corp (SLNO)|Enterprise Value FOLD (Amicus Therapeutics)|89bio.com - Enterprise Value|Total Company Value Agios Pharmaceuticals, Inc. (AGIO)|GPCR: Value Adjusted for Debt and Cash|MDXG (MiMedx Group) - Total Company Value|Rezolute Bio (RZLT) - Real Price to Acquire Entire Company|LXRX (Lexicon Pharmaceuticals) - Enterprise Value|Enterprise Value mbxbio.com (MBX)|Altimmune (ALT) - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash AARD (Aardvark Therapeutics Inc.)|Sagimet - Total Company Value|Real Price to Acquire Entire Company BioAge Labs, Inc BIOA|BMEA (Biomea Fusion, Inc.) - Enterprise Value|Quince Therapeutics (QNCX) - Total Enterprise Value|GUTS - Real Price to Acquire Entire Company|vTv Therapeutics (VTVT) - Aggregate Business Value|ATPC (Agape ATP Corp) - Enterprise Value|Enterprise Value Pluri Inc|Enterprise Value Synlogic, Inc. (SYBX)|Total Company Value LPCN (lipocine.com)|MTNB: Total Company Value|sprucebiosciences.com - Total Enterprise Value|GLTO - Total Company Value|CTCX - Total Company Value|Lumos Pharma, Inc. - Enterprise Value|ONVO (organovo.com) - Company Buyout Price|RDUS: Total Company Value